These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 25888743)

  • 41. Structure and dynamics of the gp120 V3 loop that confers noncompetitive resistance in R5 HIV-1(JR-FL) to maraviroc.
    Yuan Y; Yokoyama M; Maeda Y; Terasawa H; Harada S; Sato H; Yusa K
    PLoS One; 2013; 8(6):e65115. PubMed ID: 23840315
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Closing two doors of viral entry: intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1.
    Kopetzki E; Jekle A; Ji C; Rao E; Zhang J; Fischer S; Cammack N; Sankuratri S; Heilek G
    Virol J; 2008 May; 5():56. PubMed ID: 18452606
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Next generation sequencing reveals a high frequency of CXCR4 utilizing viruses in HIV-1 chronically infected drug experienced individuals in South Africa.
    Matume ND; Tebit DM; Gray LR; Hammarskjold ML; Rekosh D; Bessong PO
    J Clin Virol; 2018 Jun; 103():81-87. PubMed ID: 29661652
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors.
    Peters PJ; Duenas-Decamp MJ; Sullivan WM; Brown R; Ankghuambom C; Luzuriaga K; Robinson J; Burton DR; Bell J; Simmonds P; Ball J; Clapham PR
    Retrovirology; 2008 Jan; 5():5. PubMed ID: 18205925
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A post-CD4-binding step involving interaction of the V3 region of viral gp120 with host cell surface glycosphingolipids is common to entry and infection by diverse HIV-1 strains.
    Nehete PN; Vela EM; Hossain MM; Sarkar AK; Yahi N; Fantini J; Sastry KJ
    Antiviral Res; 2002 Dec; 56(3):233-51. PubMed ID: 12406507
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Distinct efficacy of HIV-1 entry inhibitors to prevent cell-to-cell transfer of R5 and X4 viruses across a human placental trophoblast barrier in a reconstitution model in vitro.
    Ayouba A; Cannou C; Nugeyre MT; Barré-Sinoussi F; Menu E
    Retrovirology; 2008 Mar; 5():31. PubMed ID: 18377645
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reduced Susceptibility to VIRIP-Based HIV-1 Entry Inhibitors Has a High Genetic Barrier and Severe Fitness Costs.
    Müller JA; Glöckle A; Gawanbacht A; Geyer M; Münch J; Kirchhoff F
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925662
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cytolysis by CCR5-using human immunodeficiency virus type 1 envelope glycoproteins is dependent on membrane fusion and can be inhibited by high levels of CD4 expression.
    LaBonte JA; Madani N; Sodroski J
    J Virol; 2003 Jun; 77(12):6645-59. PubMed ID: 12767984
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.
    Recordon-Pinson P; Soulié C; Flandre P; Descamps D; Lazrek M; Charpentier C; Montes B; Trabaud MA; Cottalorda J; Schneider V; Morand-Joubert L; Tamalet C; Desbois D; Macé M; Ferré V; Vabret A; Ruffault A; Pallier C; Raymond S; Izopet J; Reynes J; Marcelin AG; Masquelier B;
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3335-40. PubMed ID: 20530226
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Pharmacokinetics, interactions and mechanism of action of maraviroc].
    Soriano V; Poveda E
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():12-6. PubMed ID: 19133216
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Coreceptor Tropism and Maraviroc Sensitivity of Clonally Derived Ethiopian HIV-1C Strains Using an in-house Phenotypic Assay and Commonly Used Genotypic Methods.
    Kalu AW; Telele NF; Aralaguppe SG; Gebre-Selassie S; Fekade D; Marrone G; Sonnerborg A
    Curr HIV Res; 2018; 16(2):113-120. PubMed ID: 29766813
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An inducible cell-cell fusion system with integrated ability to measure the efficiency and specificity of HIV-1 entry inhibitors.
    Herschhorn A; Finzi A; Jones DM; Courter JR; Sugawara A; Smith AB; Sodroski JG
    PLoS One; 2011; 6(11):e26731. PubMed ID: 22069466
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of CXCR4 in cell-cell fusion and infection of monocyte-derived macrophages by primary human immunodeficiency virus type 1 (HIV-1) strains: two distinct mechanisms of HIV-1 dual tropism.
    Yi Y; Isaacs SN; Williams DA; Frank I; Schols D; De Clercq E; Kolson DL; Collman RG
    J Virol; 1999 Sep; 73(9):7117-25. PubMed ID: 10438797
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dual-tropic HIV type 1 isolates vary dramatically in their utilization of CCR5 and CXCR4 coreceptors.
    Toma J; Whitcomb JM; Petropoulos CJ; Huang W
    AIDS; 2010 Sep; 24(14):2181-6. PubMed ID: 20639728
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevalence of R5 and X4 HIV variants in antiretroviral treatment experienced patients with virologic failure.
    Ferrer P; Tello M; Montecinos L; Tordecilla R; Rodríguez C; Beltrán C; Guzmán MA; Ferrés M; Pérez CM; Afani A
    J Clin Virol; 2014 Jul; 60(3):290-4. PubMed ID: 24793966
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc.
    Cascajero A; Rastrojo A; Díez-Fuertes F; Hernández-Novoa B; Aguado B; Moreno S; Alcami J; Pérez-Olmeda M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29563289
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Low-Cost Compound Lignosulfonic Acid (LA) Exhibits Broad-Spectrum Anti-HIV and Anti-HSV Activity and Has Potential for Microbicidal Applications.
    Gordts SC; Férir G; D'huys T; Petrova MI; Lebeer S; Snoeck R; Andrei G; Schols D
    PLoS One; 2015; 10(7):e0131219. PubMed ID: 26132818
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of R5X4 dualtropic HIV-1 primary isolates by single chemokine co-receptor ligands.
    Ghezzi S; Menzo S; Brambilla A; Bordignon PP; Lorini AL; Clementi M; Poli G; Vicenzi E
    Virology; 2001 Feb; 280(2):253-61. PubMed ID: 11162839
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1.
    Telwatte S; Moore K; Johnson A; Tyssen D; Sterjovski J; Aldunate M; Gorry PR; Ramsland PA; Lewis GR; Paull JR; Sonza S; Tachedjian G
    Antiviral Res; 2011 Jun; 90(3):195-9. PubMed ID: 21459115
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.
    Murga JD; Franti M; Pevear DC; Maddon PJ; Olson WC
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3289-96. PubMed ID: 17005807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.